Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8423975 | 0.93 | GPR119 (0.50) | GPR119KDM4EPKM | |
| Benzene SCHEMBL3360754 | 0.89 | KDM4E (0.54) | GPR119KDM4EPKM | |
| SCHEMBL22175054 | 0.86 | KDM4E (0.47) | GPR119NR1H2KDM4EPKM | |
| SCHEMBL9697570 | 0.83 | GPR119 (0.46) | GPR119NR1H2KDM4EPKM | |
| SCHEMBL5192061 | 0.82 | GPR119 (0.51) | GPR119KDM4EPKM | |
| SCHEMBL364778 | 0.82 | NR1H2 (0.51) | GPR119NR1H2KDM4EPKM | |
| SCHEMBL344474 | 0.82 | NR1H2 (0.51) | GPR119NR1H2KDM4EPKM | |
| SCHEMBL12844537 | 0.82 | NR1H2 (0.48) | GPR119NR1H2KDM4EPKM | |
| SCHEMBL19347041 | 0.82 | NR1H2 (0.48) | GPR119NR1H2KDM4EPKM | |
| SCHEMBL6398279 | 0.82 | NR1H2 (0.51) | GPR119NR1H2KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | GPR119 124/4885NR1H2 32/4885KDM4E 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.